VEGF-A: a critical regulator of blood vessel growth

被引：253

作者：

Ferrara, Napoleone ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

EUROPEAN CYTOKINE NETWORK | 2009年 / 20卷 / 04期

关键词：

VEGF; VPF; angiogenesis; tumor; VASCULAR-PERMEABILITY FACTOR; ENDOTHELIAL-CELL; TUMOR ANGIOGENESIS; IN-VIVO; BEVACIZUMAB; THERAPY; INHIBITION; SURVIVAL; CANCER; NEOVASCULARIZATION;

D O I：

10.1684/ecn.2009.0170

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Angiogenesis is required for a variety of normal and pathological, proliferative processes. Numerous regulators of angiogenesis have been identified and characterized over the last decades. Among these, vascular endothelial growth factor (VEGF)-A appears especially important in normal development and in disease processes. Several VEGF inhibitors have been approved by the FDA for the treatment of tumors or the neovascular form of age-related macular degeneration. This article examines the molecular and biological characteristics of VEGF and also discusses preclinical and clinical studies with VEGF inhibitors and the lessons learned from these studies.

引用

收藏

页码：158 / 163

页数：6

相关论文

共 94 条

[1] Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate [J].

Adamis, AP ;

Shima, DT ;

Tolentino, MJ ;

Gragoudas, ES ;

Ferrara, N ;

Folkman, J ;

DAmore, PA ;

Miller, JW .

ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (01) :66-71

[2] SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].

AIELLO, LP ;

PIERCE, EA ;

FOLEY, ED ;

TAKAGI, H ;

CHEN, H ;

RIDDLE, L ;

FERRARA, N ;

KING, GL ;

SMITH, LEH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461

[3] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].

AIELLO, LP ;

AVERY, RL ;

ARRIGG, PG ;

KEYT, BA ;

JAMPEL, HD ;

SHAH, ST ;

PASQUALE, LR ;

THIEME, H ;

IWAMOTO, MA ;

PARK, JE ;

NGUYEN, HV ;

AIELLO, LM ;

FERRARA, N ;

KING, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487

[4] VASCULAR REACTIONS OF NORMAL AND MALIGNANT TISSUES INVIVO .1. VASCULAR REACTIONS OF MICE TO WOUNDS AND TO NORMAL AND NEOPLASTIC TRANSPLANTS [J].

ALGIRE, GH ;

CHALKLEY, HW .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1945, 6 (01) :73-85

[5] Lymphangiogenesis in development and human disease [J].

Alitalo, K ;

Tammela, T ;

Petrova, TV .

NATURE, 2005, 438 (7070) :946-953

[6] VASCULAR ENDOTHELIAL GROWTH-FACTOR ACTS AS A SURVIVAL FACTOR FOR NEWLY FORMED RETINAL-VESSELS AND HAS IMPLICATIONS FOR RETINOPATHY OF PREMATURITY [J].

ALON, T ;

HEMO, I ;

ITIN, A ;

PEER, J ;

STONE, J ;

KESHET, E .

NATURE MEDICINE, 1995, 1 (10) :1024-1028

[7] Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].

Benjamin, LE ;

Golijanin, D ;

Itin, A ;

Pode, D ;

Keshet, E .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165

[8] Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].

Brown, David M. ;

Kaiser, Peter K. ;

Michels, Mark ;

Soubrane, Gisele ;

Heier, Jeffrey S. ;

Kim, Robert Y. ;

Sy, Judy P. ;

Schneider, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444

[9]

Broxmeyer HE, 1995, INT J HEMATOL, V62, P203

[10] Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].

Carmeliet, P ;

Ferreira, V ;

Breier, G ;

Pollefeyt, S ;

Kieckens, L ;

Gertsenstein, M ;

Fahrig, M ;

Vandenhoeck, A ;

Harpal, K ;

Eberhardt, C ;

Declercq, C ;

Pawling, J ;

Moons, L ;

Collen, D ;

Risau, W ;

Nagy, A .

NATURE, 1996, 380 (6573) :435-439

← 1 2 3 4 5 6 7 8 9 10 →